{"id":"vir-7831","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the spike protein, preventing the virus from entering host cells. This neutralization prevents the virus from causing infection and replication.","oneSentence":"VIR-7831 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:56.559Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT04870333","phase":"PHASE2, PHASE3","title":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-02-19","conditions":"Covid19","enrollment":2240},{"nctId":"NCT05135650","phase":"PHASE1","title":"Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-01-25","conditions":"COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":20},{"nctId":"NCT05210101","phase":"PHASE2","title":"A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals","status":"COMPLETED","sponsor":"Sophia Koo, M.D.","startDate":"2022-02-07","conditions":"SARS CoV 2 Infection","enrollment":93},{"nctId":"NCT04913675","phase":"PHASE3","title":"Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.","status":"TERMINATED","sponsor":"Vir Biotechnology, Inc.","startDate":"2021-06-10","conditions":"Covid19","enrollment":1065},{"nctId":"NCT05780281","phase":"PHASE3","title":"VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":"COVID-19","enrollment":367},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04779879","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2021-02-18","conditions":"Covid19","enrollment":354},{"nctId":"NCT04545060","phase":"PHASE2, PHASE3","title":"VIR-7831 for the Early Treatment of COVID-19 in Outpatients","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-08-27","conditions":"Covid19","enrollment":1057},{"nctId":"NCT04634409","phase":"PHASE2","title":"A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-29","conditions":"COVID-19","enrollment":1755}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sotrovimab","GSK4182136"],"phase":"phase_3","status":"active","brandName":"VIR-7831","genericName":"VIR-7831","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"VIR-7831 is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}